Susquehanna International Group, LLP Krystal Biotech, Inc. Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

A detailed history of Susquehanna International Group, LLP transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 9,554 shares of KRYS stock, worth $1.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

9,554

Previous 5,484 74.22%

Holding current value

$1.7 Million

Previous $1.01 Million 72.49%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$174.7 - $213.66 $711,029 - $869,596	4,070 Added 74.22%	9,554 $1.74 Million
Q2 2024 Aug 15, 2024	SELL	$153.12 - $183.64 $14.7 Million - $17.6 Million	-96,073 Reduced 94.6%	5,484 $1.01 Million
Q1 2024 May 07, 2024	BUY	$108.01 - $179.35 $10.1 Million - $16.8 Million	93,515 Added 1162.83%	101,557 $18.1 Million
Q4 2023 Feb 14, 2024	BUY	$96.0 - $128.29 $86,208 - $115,204	898 Added 12.57%	8,042 $997,000
Q3 2023 Nov 14, 2023	BUY	$108.51 - $130.22 $82,684 - $99,227	762 Added 11.94%	7,144 $828,000
Q2 2023 Aug 11, 2023	SELL	$78.48 - $130.32 $1.55 Million - $2.57 Million	-19,737 Reduced 75.57%	6,382 $749,000
Q1 2023 May 16, 2023	BUY	$72.39 - $84.27 $1.3 Million - $1.51 Million	17,927 Added 218.84%	26,119 $2.09 Million
Q4 2022 Feb 14, 2023	SELL	$63.14 - $79.9 $761,342 - $963,434	-12,058 Reduced 59.55%	8,192 $648,000
Q3 2022 Nov 14, 2022	BUY	$64.85 - $82.4 $259,335 - $329,517	3,999 Added 24.61%	20,250 $1.41 Million
Q2 2022 Aug 15, 2022	BUY	$48.93 - $73.47 $55,682 - $83,608	1,138 Added 7.53%	16,251 $1.07 Million
Q1 2022 May 16, 2022	BUY	$51.99 - $72.11 $84,691 - $117,467	1,629 Added 12.08%	15,113 $1.01 Million
Q4 2021 Feb 14, 2022	BUY	$39.81 - $88.24 $40,924 - $90,710	1,028 Added 8.25%	13,484 $943,000
Q3 2021 Nov 15, 2021	BUY	$52.01 - $71.77 $252,508 - $348,443	4,855 Added 63.87%	12,456 $650,000
Q2 2021 Aug 11, 2021	SELL	$62.14 - $81.82 $178,714 - $235,314	-2,876 Reduced 27.45%	7,601 $517,000
Q1 2021 May 17, 2021	SELL	$59.42 - $85.46 $696,758 - $1 Million	-11,726 Reduced 52.81%	10,477 $807,000
Q4 2020 Feb 16, 2021	BUY	$40.64 - $61.38 $403,352 - $609,196	9,925 Added 80.84%	22,203 $1.33 Million
Q3 2020 Nov 16, 2020	SELL	$37.76 - $48.49 $209,719 - $269,313	-5,554 Reduced 31.15%	12,278 $529,000
Q2 2020 Aug 14, 2020	BUY	$37.03 - $60.0 $418,179 - $677,580	11,293 Added 172.7%	17,832 $739,000
Q1 2020 May 15, 2020	BUY	$35.02 - $65.64 $228,995 - $429,219	6,539 New	6,539 $283,000
Q4 2019 Feb 14, 2020	SELL	$33.17 - $65.23 $219,917 - $432,474	-6,630 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$34.72 - $51.3 $14,443 - $21,340	416 Added 6.69%	6,630 $230,000
Q2 2019 Aug 16, 2019	BUY	$27.2 - $41.2 $169,020 - $256,016	6,214 New	6,214 $250,000
Q2 2019 Aug 14, 2019	SELL	$27.2 - $41.2 $1.24 Million - $1.87 Million	-45,493 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$19.86 - $32.9 $532,168 - $881,588	26,796 Added 143.32%	45,493 $1.5 Million
Q4 2018 Feb 14, 2019	BUY	$15.03 - $25.38 $281,015 - $474,529	18,697 New	18,697 $389,000

Others Institutions Holding KRYS

# of Institutions

310

Shares Held

24.4M

Call Options Held

483K

Put Options Held

364K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.57B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Krystal Biotech, Inc. Transaction History